Dr. David Brindley, PhD
Dr. Brindley's work is designed to improve the treatment of cancers, particularly breast cancer. His research focuses on how cancer are activated by a compound called lysophosphatidate (LPA). LPA increases tumour growth, the spread of the cancer (metastasis) and it decreases the effectiveness of chemotherapies and radiotherapy. Dr. Brindley studies clinically approved drugs that block LPA production or increase its degradation to introduce these as new cancer treatments particularly for improving the effectiveness of radiotherapy and decreasing its adverse side effects.
Dr. Brindley has received many awards that recognize his research including being elected as a Fellow of the Royal Society of Canada. He was a member of the committee that established the Cancer Research Institute of Northern Alberta and now serves as a Co-Director.